After parting ways with its margarines in 2017 and its Lipton teas a few weeks ago, Unilever (Magnum, Dove, Maille, Rexona…) intends to accelerate its shift towards more dynamic… and more profitable activities.
Even if it means moving away from some of its professions such as food and home care.
This weekend, the British group thus confirmed its strong interest in the consumer health activities of its compatriot GlaxoSmithKline (GSK).
Read also
Unilever is making its work revolution
Co-owned with the American Pfizer (32%), this division with more than 11 billion euros in turnover includes, among other things, Sensodyne toothpaste, the anti-inflammatory Voltarene and the painkillers Advil and Panadol.
Upon the creation of its subsidiary with Pfizer three years ago, GSK announced its intention to list it on the stock market.
However, according to the laboratory, Unilever has already returned to the charge several times, offering it up to 50 billion pounds (60 billion euros) for its division, during…
This article is for subscribers only.
You have 79% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
I ENJOY IT
Already subscribed?
Login
